Capricor Therapeutics, Inc. To Present ALLSTAR Phase I Trial Data At American College of Cardiology Annual Meeting 2014

Published: Mar 31, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOS ANGELES, March 28, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today announced Co-founder and Scientific Advisory Board Chairman, Dr. Eduardo Marbán, M.D., Ph.D., will present at the American College of Cardiology 63rd Annual Scientific Session and Expo, taking place March 29-31, 2014 in Washington, DC. Dr. Marbán's presentation will highlight positive data demonstrating that the Phase I portion of the Company's ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR) Phase I/II trial met its primary endpoint of safety.

Help employers find you! Check out all the jobs and post your resume.

Back to news